Hengehold Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.67M Buy
1,393
+103
+8% +$105K 0.13% 88
2026
Q1
$1.19M Buy
1,290
+343
+36% +$348K 0.1% 92
2025
Q4
$1.02M Buy
947
+379
+67% +$362K 0.09% 97
2025
Q3
$434K Buy
568
+17
+3% +$12.7K 0.04% 150
2025
Q2
$430K Hold
551
0.04% 146
2025
Q1
$455K Buy
551
+2
+0.4% +$1.66K 0.04% 133
2024
Q4
$424K Sell
549
-57
-9% -$47.2K 0.04% 135
2024
Q3
$537K Buy
606
+82
+16% +$73.7K 0.05% 115
2024
Q2
$475K Buy
524
+62
+13% +$49.6K 0.05% 116
2024
Q1
$360K Sell
462
-24
-5% -$17.1K 0.04% 138
2023
Q4
$283K Hold
486
0.03% 147
2023
Q3
$261K Hold
486
0.03% 143
2023
Q2
$228K Buy
+486
New +$204K 0.03% 155
2019
Q1
Sell
-2,611
Closed -$302K 125
2018
Q4
$302K Sell
2,611
-60
-2% -$6.7K 0.1% 81
2018
Q3
$287K Sell
2,671
-1,000
-27% -$100K 0.07% 95
2018
Q2
$313K Hold
3,671
0.08% 82
2018
Q1
$284K Buy
3,671
+21
+0.6% +$1.69K 0.07% 95
2017
Q4
$308K Buy
+3,650
New +$311K 0.08% 92

Other funds holding LLY

Hengehold Capital Management's LLY Position: Q2 2026 in Review

Hengehold Capital Management increased its Eli Lilly (LLY) stake by 8% in Q2 2026, buying an estimated $105K and bringing the position to 1,393 shares worth $1.67M. The position accounts for 0.13% of the portfolio, ranked #88.

Hengehold Capital Management first reported a position in LLY in Q4 2017 and has held it in 18 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Hengehold Capital Management held 1,393 shares of Eli Lilly worth $1.67M as of Q2 2026.
  • Hengehold Capital Management bought 103 Eli Lilly shares in Q2 2026, an estimated $105K.
  • Eli Lilly made up 0.13% of Hengehold Capital Management's portfolio in Q2 2026, its #88 holding.
  • Hengehold Capital Management first reported a position in Eli Lilly in Q4 2017 and has held it in 18 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Hengehold Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.